>> With lomucin you get the mucoregulator and the anti-inflamatory rolled into one <<
Given that DYAX now has orphan status in CF as an anti-inflammatory, it may be a more of a negative than a positive that Lomucin is partly an anti-inflammatory. I would not be surprised to see GENR tone down any discussion of Lomucin’s anti-inflammatory properties in order to steer clear of DYAX’s orphan-drug exclusivity.
If there is bona fide synergy between Lomucin and DYAX’s drug, then the above considerations would not apply.
Market Data 
Markets 
AI
